Meet In CommonNewsRSS feeds

Local

Who was the late Mexican cartel ‘boss of bosses’ convicted of killing a US DEA agent?

A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Source: Madison365

By Uriel Blanco, CNN Editor’s note: Lee este artículo en español. (CNN) — Miguel Ángel Félix Gallardo, a founder of the first major drug cartel in Mexico, died on Sunday at the age of 80 in a hospital in Guadalajara, Jalisco. As one of the leaders of the Guadalajara Cartel, the so-called “boss of bosses” laid the foundations for large-scale drug trafficking in the country and helped transform cocaine routes to the United States. Félix Gallardo had been convicted over the kidnapping, torture and death of US Drug Enforcement Administration (DEA) agent Enrique “Kiki” Camarena in 1985, a crime that caused a diplomatic crisis between Mexico and Washington. Local security authorities reported that the former cartel leader died due to multiple organ failure after several years of health problems. He had been transferred to the hospital from the Puente Grande maximum security prison, where he had been held since 2015.

This excerpt comes from the named source. Read the original for the full reporting.

Read the original at Madison365

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

Community Poll

Officials should step aside from decisions involving a potential personal conflict of interest.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

Would you want a doctor to give you a fake pill if the lie might make you feel better?

A patient has persistent symptoms that have not responded to standard treatments. A harmless placebo may help, but its effect could weaken if the clinician fully explains that it contains no active medicine.

Can a beneficial deception respect the person it helps?

Explore this quandary